[HTML][HTML] PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) …
MT Dillon, Z Boylan, D Smith, J Guevara… - Clinical and …, 2018 - Elsevier
MT Dillon, Z Boylan, D Smith, J Guevara, K Mohammed, C Peckitt, M Saunders, U Banerji…
Clinical and Translational Radiation Oncology, 2018•ElsevierPATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in
combination with palliative radiotherapy. Here, we describe the protocol for this study, which
opened in 2014 and is currently recruiting and comprises dose escalation of both drug and
radiotherapy, and expansion cohorts.
combination with palliative radiotherapy. Here, we describe the protocol for this study, which
opened in 2014 and is currently recruiting and comprises dose escalation of both drug and
radiotherapy, and expansion cohorts.
Abstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Elsevier
